top of page

Case Study

Large Pharmaceutical Generics Manufacturer from China

Read more:



Life Sciences





Number of Employees

1000 - 5000


Our collaboration unfolded with a leading pharmaceutical generics manufacturer headquartered in China, boasting a robust workforce ranging from 1000 to 5000 employees. With aspirations to penetrate the DACH (Germany, Austria, Switzerland) and Benelux (Belgium, Netherlands, Luxembourg) markets, this pharmaceutical giant sought Avomind's expertise to establish a strong foothold in continental Europe.


The primary challenge for our client was navigating the intricacies of expanding into new markets within Europe while maintaining the high standards expected in the pharmaceutical industry. With a focus on DACH and Benelux, the task at hand was not only to penetrate these markets but also to establish a solid operational infrastructure and commercial presence.


Recognizing the complexity of expanding into new markets while upholding pharmaceutical industry standards, Avomind devised a strategic solution for our client, a leading Chinese pharmaceutical generics manufacturer eyeing entry into the DACH and Benelux regions of Europe. Leveraging our extensive network and sector expertise, we orchestrated the recruitment of key personnel, including Regional Heads for DACH and the Netherlands, along with a dedicated commercial team. These hires brought not only deep market knowledge but also a track record of successful pharmaceutical commercialization, positioning our client strongly for market entry and expansion.

Through close collaboration with the client, our appointed Regional Heads developed tailored strategies for market penetration and growth, navigating regulatory landscapes and forging strategic partnerships. This meticulous approach, coupled with the expertise of our recruited talent, enabled our client to swiftly establish a robust operational infrastructure and commercial presence in Europe. With Avomind's support, our client laid the groundwork for sustained success in the competitive pharmaceutical generics market of the DACH and Benelux regions.

Related Case Studies
bottom of page